New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 31, 2013
13:26 EDTSPPI, AGNSpectrum regaining rights to bladder cancer drug not a positive, The Street says
Allergan (AGN) returning the rights to bladder cancer drug apaziquone back to Spectrum Pharmaceuticals (SPPI) is not a positive for Spectrum, contends The Street's Adam Feuerstein. Feuerstein says that Spectrum will need to conduct an additional phase III study of the drug and that the company is going to file for FDA approval based on two, separate studies that each failed to hit their primary endpoints with statistical significance. The Fly notes that Spectrum shares are up about 6.9% to $12.75 in early afternoon trading. Reference Link
News For SPPI;AGN From The Last 14 Days
Check below for free stories on SPPI;AGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 17, 2014
17:08 EDTSPPISpectrum names Joseph Turgeon COO
Spectrum disclosed in a regulatory filing that effective April 17, Spectrum Pharmaceuticals appointed Joseph Turgeon as its President and COO. Mr. Turgeon will have global responsibility for leading Commercial Operations, Medical and Clinical Development and Pharmaceutical Operations. On April 17, Ken Keller resigned from his position as EVP and COO of the company in order to assume the role of CEO of an organization on the east coast. Mr. Keller will continue to be employed by the company through April 28 in order to assist with the transition. Kellerís resignation was not the result of any disagreement with the company on any matter relating to the companyís operations, policies or practices.
April 16, 2014
10:00 EDTAGNOn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: A10 Networks (ATEN) initiated with a Buy at BofA/Merrill... Actavis (ACT) initiated with a Buy at Sterne Agee... Allergan (AGN) initiated with a Buy at Sterne Agee... Autohome (ATHM) initiated with a Neutral at Credit Suisse... BitAuto (BITA) initiated with an Outperform at Credit Suisse... Centene (CNC) initiated with a Neutral at UBS... Endo International (ENDP) initiated with a Buy at Sterne Agee... FS Investment (FSIC) initiated with an Overweight at Evercore... Hertz (HTZ) initiated with a Buy at Gabelli... Hilton (HLT) initiated with a Hold at Jefferies... Hospira (HSP) initiated with a Neutral at Sterne Agee... ImmunoGen (IMGN) initiated with a Buy at Canaccord... Impax (IPXL) initiated with a Neutral at Sterne Agee... Imperva (IMPV) assumed with a Neutral at Wedbush... Ingredion (INGR) initiated with an Outperform at Credit Suisse... Laredo Petroleum (LPI) initiated with an Outperform at RW Baird... Lpath (LPTN) initiated with a Buy at Canaccord... MediWound (MDWD) initiated with an Outperform at Oppenheimer... Medivation (MDVN) initiated with a Hold at Canaccord... NPS Pharmaceuticals (NPSP) assumed with a Buy at Canaccord... Nimble Storage (NMBL) initiated with a Market Perform at Raymond James... Regeneron (REGN) initiated with a Buy at Canaccord... Salix (SLXP) initiated with a Buy at Sterne Agee... Sibanye Gold (SBGL) initiated with an Outperform at Imperial Capital... Teva (TEVA) initiated with a Neutral at Sterne Agee... Wipro (WIT) assumed with a Hold at Jefferies.
07:04 EDTAGNAllergan initiated with a Buy at Sterne Agee
Target $142.
April 11, 2014
18:44 EDTAGNJ&J halting development of Botox competitor, WSJ says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use